Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients

被引:11
作者
van Hoogstraten, L. M. C. [1 ,4 ]
van Gennep, E. J. [2 ]
Kiemeney, L. A. L. M. [3 ,4 ]
Witjes, J. A. [3 ]
Voskuilen, C. S. [5 ]
Deelen, M. [6 ]
Mertens, L. S. [5 ]
Meijer, R. P. [7 ]
Boormans, J. L. [8 ]
Robbrecht, D. G. J. [9 ]
Beerepoot, L. V. [10 ]
Verhoeven, R. H. A. [1 ,11 ]
Ripping, T. M. [1 ]
van Rhijn, B. W. G.
Aben, K. K. H. [1 ,4 ]
Hermans, T. J. N.
机构
[1] Netherlands Comprehens Canc Org, Dept Res & Dev, Utrecht, Netherlands
[2] Leiden Univ, Med Ctr, Dept Urol, Leiden, Netherlands
[3] Radboud Univ Nijmegen Med Ctr, Dept Urol, Nijmegen, Netherlands
[4] Radboud Univ Nijmegen Med Ctr, Radboud Inst Hlth Sci, Nijmegen, Netherlands
[5] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Urol, Amsterdam, Netherlands
[6] Maastricht Univ Med Ctr, Dept Urol, Maastricht, Netherlands
[7] Univ Med Ctr Utrecht, Dept Oncol Urol, Utrecht, Netherlands
[8] Erasmus MC, Dept Urol, Rotterdam, Netherlands
[9] Erasmus MC, Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
[10] Elisabeth TweeSteden Hosp, Dept Med Oncol, Tilburg, Netherlands
[11] Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Dept Med Oncol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
关键词
Bladder cancer; Neoadjuvant chemotherapy; Downstaging; Lymph node metastases; Radical cystectomy; TRANSURETHRAL RESECTION; DISSECTION; MANAGEMENT; IMPACT; PET/CT;
D O I
10.1007/s00345-021-03839-7
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose Little is known about the prevalence of occult lymph node metastases (LNM) in muscle-invasive bladder cancer (MIBC) patients with pathological downstaging of the primary tumor. We aimed to estimate the prevalence of occult LNM in patients without residual MIBC at radical cystectomy (RC) with or without neoadjuvant chemotherapy (NAC) or neoadjuvant radiotherapy (NAR), and to assess overall survival (OS). Methods Patients with cT2-T4aN0M0 urothelial MIBC who underwent RC plus pelvic lymph node dissection (PLND) with curative intent between January 1995-December 2013 (retrospective Netherlands Cancer Registry (NCR) cohort) and November 2017-October 2019 (prospective NCR-BlaZIB cohort (acronym in Dutch: BlaaskankerZorg In Beeld; in English: Insight into bladder cancer care)) were identified from the nationwide NCR. The prevalence of occult LNM was calculated and OS of patients with y)pT2N0 vs. y)pT2N+ disease was estimated by the Kaplan-Meier method. Results In total, 4657 patients from the NCR cohort and 760 patients from the NCR-BlaZIB cohort were included. Of 1374 patients downstaged to y)pT2, 4.3% (N = 59) had occult LNM 4.1% (N = 49) of patients with cT2-disease and 5.6% (N = 10) with cT3-4a-disease. This was 4.0% (N = 44) in patients without NAC or NAR, 4.5% (N = 10) in patients with NAC, and 13.5% (N = 5) in patients with NAR but number of patients treated with NAR and downstaged disease was small. The prevalence of y)pT2N+ disease was 4.2% (N = 48) in the NCR cohort and 4.6% (N = 11) in the NCR-BlaZIB cohort. For patients with y)pT2N+ and y)pT2N0, median OS was 3.5 years (95% CI 2.5-8.9) versus 12.9 years (95% CI 11.7-14.0), respectively. Conclusion Occult LNM were found in 4.3% of patients with cT2-4aN0M0 MIBC with (near-) complete downstaging of the primary tumor following RC plus PLND. This was regardless of NAC or clinical T-stage. Patients with occult LNM showed considerable worse survival. These results can help in counseling patients for bladder-sparing treatments.
引用
收藏
页码:111 / 118
页数:8
相关论文
共 29 条
[1]   Fewer tumour draining sentinel nodes in patients with progressing muscle invasive bladder cancer, after neoadjuvant chemotherapy and radical cystectomy [J].
Alvaeus, Julia ;
Rosenblatt, Robert ;
Johansson, Markus ;
Alamdari, Farhood ;
Jakubczyk, Tomasz ;
Holmstrom, Benny ;
Hemdan, Tammer ;
Huge, Ylva ;
Aljabery, Firas ;
Gabrielsson, Susanne ;
Riklund, Katrine ;
Winqvist, Ola ;
Sherif, Amir .
WORLD JOURNAL OF UROLOGY, 2020, 38 (09) :2207-2213
[2]  
[Anonymous], EAU 2021 CIRC TUM CE
[3]   Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data [J].
Audenet, Francois ;
Waingankar, Nikhil ;
Ferket, Bart S. ;
Niglio, Scot A. ;
Marqueen, Kathryn E. ;
Sfakianos, John P. ;
Galsky, Matthew D. .
JOURNAL OF UROLOGY, 2018, 200 (05) :996-1003
[4]  
Bierley JD., 2017, UICC TNM Classification of Malignant Tumours. Digestive System Tumours, V8th
[5]   The Impact of the Extent of Lymphadenectomy on Oncologic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Systematic Review [J].
Bruins, Harman M. ;
Veskimae, Erik ;
Hernandez, Virginia ;
Imamura, Mari ;
Neuberger, Molly M. ;
Dahm, Philip ;
Stewart, Fiona ;
Lam, Thomas B. ;
N'Dow, James ;
van der Heijden, Antoine G. ;
Comperat, Eva ;
Cowan, Nigel C. ;
De Santis, Maria ;
Gakis, Georgios ;
Lebret, Thierry ;
Ribal, Maria J. ;
Sherif, Amir ;
Witjes, J. Alfred .
EUROPEAN UROLOGY, 2014, 66 (06) :1065-1077
[6]  
Casparie M, 2007, CELL ONCOL, V29, P19
[7]   Lymph Node Dissection Technique Is More Important Than Lymph Node Count in Identifying Nodal Metastases in Radical Cystectomy Patients: A Comparative Mapping Study [J].
Dorin, Ryan P. ;
Daneshmand, Siamak ;
Eisenberg, Manuel S. ;
Chandrasoma, Shahin ;
Cai, Jie ;
Miranda, Gus ;
Nichols, Peter W. ;
Skinner, Donald G. ;
Skinner, Eila C. .
EUROPEAN UROLOGY, 2011, 60 (05) :946-952
[8]  
Fritz A. G., 2013, INT CLASSIFICATION D
[9]   Diagnostic Accuracy of F-18 FDG PET/CT for Preoperative Lymph Node Staging in Newly Diagnosed Bladder Cancer Patients: A Systematic Review and Meta-Analysis [J].
Ha, Hong Ku ;
Koo, Phillip J. ;
Kim, Seong-Jang .
ONCOLOGY, 2018, 95 (01) :31-38
[10]   Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer [J].
Hermans, T. J. N. ;
Voskuilen, C. S. ;
Deelen, M. ;
Mertens, L. S. ;
Horenblas, S. ;
Meijer, R. P. ;
Boormans, J. L. ;
Aben, K. K. ;
van der Heijden, M. S. ;
Pos, F. J. ;
de Wit, R. ;
Beerepoot, L. V. ;
Verhoeven, R. H. A. ;
van Rhijn, B. W. G. .
INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (06) :1453-1459